New Teva-Kowa Venture Plans Expansion In Japan’s Generics Market
This article was originally published in PharmAsia News
Executive Summary
Israel's Teva Pharmaceutical Industries plans to expand its presence in Japan through its new joint venture with Kowa Pharma. With a planned investment of more than $110.7 million by 2015, Teva hopes to bring more than 200 generic drugs to the Japanese market, mainly for treating cancer, cholesterol and high blood pressure. With the expansion, the Teva-Kowa venture plans to add about 400 workers and take charge of 40 Teva generics already on the market. Teva-Kowa's president said the venture also will seek friendly partnerships, mergers and acquisitions so it can have 10 percent of the generics market. (Click here for more - a subscription may be required